https://www.aigom.it/wp-content/uploads/2024/11/LOC.12.11.png1134960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-10 14:16:252024-11-10 14:16:25CHARACTERISTICS AND CLINICAL OUTCOMES OF BREAST CANCER IN YOUNG BRCA CARRIERS ACCORDING TO TUMOR HISTOLOGY
https://www.aigom.it/wp-content/uploads/2024/11/ART.5-11.png1238950Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-05 04:31:132024-11-05 04:31:13NEOADJUVANT CHEMOTHERAPY WITH OXALIPLATIN AND FLUOROPYRIMIDINE VERSUS UPFRONT SURGERY FOR LOCALLY ADVANCED COLON CANCER: THE RANDOMIZED, PHASE III OPTICAL TRIAL.
https://www.aigom.it/wp-content/uploads/2024/10/ART.29.10.png1181960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-10-28 08:53:462024-10-28 08:53:46NEOADJUVANT DOCETAXEL, OXALIPLATIN, AND S-1 PLUS SURGERY AND ADJUVANT S-1 FOR RESECTABLE ADVANCED GASTRIC CANCER: UPDATED OVERALL SURVIVAL OUTCOMES FROM PHASE III PRODIGY.
https://www.aigom.it/wp-content/uploads/2024/10/ART22.10.png1080960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-10-21 09:26:222024-10-21 09:26:22ELACESTRANT (ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER) VERSUS STANDARD ENDOCRINE THERAPY FOR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER: RESULTS FROM THE RANDOMIZED PHASE III EMERALD TRIAL.
https://www.aigom.it/wp-content/uploads/2024/10/ART.15.10.png1277960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-10-14 07:39:232024-10-14 07:39:23TRASTUZUMAB DERUXTECAN AFTER ENDOCRINE THERAPY IN METASTATIC BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2024/10/art.8.10.png1232960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-10-07 07:49:582024-10-07 07:49:58NEOADJUVANT NIVOLUMAB AND IPILIMUMAB IN RESECTABLE STAGE III MELANOMA.
https://www.aigom.it/wp-content/uploads/2024/10/ART.1.10.png1284960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-10-01 07:39:072024-10-01 07:39:07OVERALL SURVIVAL WITH PEMBROLIZUMAB IN EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2024/09/loc.art_.24.9.png1280960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-09-23 07:08:262024-09-23 07:12:33CORTICOSTEROIDS FOR IMMUNE-RELATED ADVERSE EVENTS AND CHECKPOINT INHIBITOR EFFICACY: ANALYSIS OF SIX CLINICAL TRIALS.
https://www.aigom.it/wp-content/uploads/2024/09/art.17.9.png1179960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-09-17 08:01:012024-09-17 08:01:01PEMBROLIZUMAB PLUS CARBOPLATIN AND PACLITAXEL AS FIRST-LINE THERAPY FOR RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (KEYNOTE-B10): A SINGLE-ARM PHASE IV TRIAL.
https://www.aigom.it/wp-content/uploads/2024/09/art.10.09.png1179960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-09-09 07:33:322024-09-09 07:33:32DURABILITY OF RESPONSE WITH SELPERCATINIB IN PATIENTS WITH RET-ACTIVATED THYROID CANCER: LONG-TERM SAFETY AND EFFICACY FROM LIBRETTO-001.
